Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-04 · 1881 (2) · 189550
DOI: 10.1016/j.bbcan.2026.189550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-04. Verfasst von Haitong Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; Breast Center, West China Hospital, Sichuan U…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Trastuzumab, Camptothecin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 192 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China, Sichuan University.
Abstract (Originalsprache)
Trastuzumab deruxtecan (T-DXd) has emerged as a revolutionary antibody-drug conjugate (ADC) that has shown remarkable clinical efficacy across multiple HER2-expressing tumor types. Comprising a humanized anti-HER2 monoclonal antibody linked to a potent topoisomerase I inhibitor via a cleavable and stable tetrapeptide-based linker, T-DXd integrates the specificity of targeted therapy with the cytotoxic potency of chemotherapy. As the most promising ADC in the era of precision oncology, T-DXd has been approved to treat a series of malignant tumors. However, its widespread clinical application is challenged by treatment-related adverse events, the emergence of drug resistance, and uncertainties in biomarker-guided patient selection. This review provides a comprehensive overview of T-DXd's molecular design, mechanisms of action, and major findings from key clinical trials. It also examines resistance pathways and safety considerations, and discusses strategies to optimize therapeutic outcomes, including rational combination approaches with immune checkpoint inhibitors or other targeted agents. Finally, we explore future directions in T-DXd development, emphasizing the importance of precision medicine, biomarker refinement, and next-generation ADC engineering to further enhance efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; Breast Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610068, China.
- Departments of Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Di…
- Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; Breast Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610068, China. Electronic address: chenjie…
Förderung
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
- Sichuan University
Zitieren
APA
Xie, H., Wang, X., Zhang, P., Li, Q., & Chen, J. (2026). Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(2), 189550. https://doi.org/10.1016/j.bbcan.2026.189550
Vancouver
Xie H, Wang X, Zhang P, Li Q, Chen J. Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(2):189550. doi:10.1016/j.bbcan.2026.189550
BibTeX
@article{Xie2026,
author = {Xie, Haitong and Wang, Xin and Zhang, Peixuan and Li, Qintong and Chen, Jie},
title = {Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {2},
pages = {189550},
doi = {10.1016/j.bbcan.2026.189550}
}
EUVIMED